NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

HLUNB.DK

42.42

-0.98%↓

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

HLUNB.DK

42.42

-0.98%↓

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

HLUNB.DK

42.42

-0.98%↓

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

HLUNB.DK

42.42

-0.98%↓

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

NOVO.B.DK

277.65

+1.83%↑

GMAB.DK

1,689.5

-0.03%↓

HLUNB.DK

42.42

-0.98%↓

ZEAL.DK

309.2

+3.27%↑

AMBUB.DK

65.2

+3.33%↑

Home・Listă Acțiuni・Coloplast A-S (Class B)

Coloplast A-S (Class B)

Închisă

402 1.88

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

400.6

Maxim

402.1

Indicatori cheie
By Trading Economics
Venit	522M 1.4B
Vânzări	83M 7B
P/E Medie Sector	23.047 49.8
EPS	6.32
Randament dividend	5.71
Marjă de profit	19.835
Angajați	16,983
EBITDA	309M 2.3B

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+11.86% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	5.71% 2.25%
Următoarele câștiguri	12 mai 2026
Data viitoare de dividende	20 mai 2026
Următoarea dată ex-dividende	18 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-27B 92B
Deschiderea anterioară	400.12
Închiderea anterioară	402

Coloplast A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 mai 2026, 23:58 UTC

Câștiguri

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mai 2026, 22:57 UTC

Câștiguri

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mai 2026, 23:52 UTC

Câștiguri

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mai 2026, 23:11 UTC

Câștiguri

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mai 2026, 23:06 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mai 2026, 23:05 UTC

Câștiguri

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mai 2026, 23:04 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mai 2026, 23:03 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mai 2026, 23:03 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mai 2026, 23:02 UTC

Câștiguri

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mai 2026, 22:42 UTC

Câștiguri

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mai 2026, 22:33 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 22:32 UTC

Câștiguri

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mai 2026, 22:31 UTC

Câștiguri

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mai 2026, 22:31 UTC

Câștiguri

Macquarie: 68% of FY Income From International >MQG.AU

7 mai 2026, 22:30 UTC

Câștiguri

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mai 2026, 22:30 UTC

Câștiguri

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mai 2026, 22:29 UTC

Câștiguri

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mai 2026, 22:28 UTC

Câștiguri

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mai 2026, 22:28 UTC

Câștiguri

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mai 2026, 22:27 UTC

Câștiguri

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mai 2026, 22:27 UTC

Câștiguri

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mai 2026, 22:26 UTC

Câștiguri

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mai 2026, 22:25 UTC

Câștiguri

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparație

Modificare preț

Coloplast A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

11.86% sus

Prognoză pe 12 luni

Medie 901.38 DKK 11.86%

Maxim 1,056 DKK

Minim 720 DKK

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruColoplast A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Coloplast A-S (Class B) - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.